
TY  - JOUR
TI  - Poster Sessions
JO  - Allergy
VL  - 64
IS  - s90
SN  - 0105-4538
UR  - https://doi.org/10.1111/j.1398-9995.2009.02076.x
DO  - doi:10.1111/j.1398-9995.2009.02076.x
SP  - 179
EP  - 538
PY  - 2009
ER  - 

TY  - JOUR
AU  - Hindmarch, I.
TI  - Expanding the horizons of depression: beyond the monoamine hypothesis
JO  - Human Psychopharmacology: Clinical and Experimental
JA  - Hum. Psychopharmacol. Clin. Exp.
VL  - 16
IS  - 3
SN  - 0885-6222
UR  - https://doi.org/10.1002/hup.288
DO  - doi:10.1002/hup.288
SP  - 203
EP  - 218
KW  - antidepressants
KW  - depression
KW  - mode of action
KW  - monoamine hypothesis
KW  - pathophysiology
PY  - 2001
AB  - Abstract The monoamine hypothesis has dominated our understanding of depression and of pharmacological approaches to its management and it has produced several generations of antidepressant agents, ranging from the monoamine oxidase inhibitors (MAOIs), through tricyclics (TCAs) and selective serotonin reuptake inhibitors (SSRIs), to the recently introduced selective noradrenaline reuptake inhibitor (NARI), reboxetine. Greater receptor selectivity has improved tolerability, but not efficacy, when newer compounds are compared with the original tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors. Essentially, the newer antidepressants have the same distinguishing feature as older ones, i.e. acute enhancement of monoaminergic neurotransmission. The monoamine hypothesis cannot conclusively link the acute biochemical action of antidepressants on monoamine levels with their delayed clinical effect of 10?14 days, nor can it explain the mode of action of antidepressants that are effective despite being very weak inhibitors of monoaminergic transmission (e.g. iprindole) or, incongruously, enhancing monoamine uptake (e.g. tianeptine). Compared with other fields of medicine, there has been a lack of progress in understanding the pathophysiology of depression and producing truly novel antidepressant agents. Other biological approaches to depression, such as overactivity of the hypothalamic?pituitary?adrenal axis, hippocampal neural plasticity in response to stress, and the link between the inflammatory response and depression, offer new approaches to finding pharmacological agents, aided by improved techniques for visualising the human brain, better animal models, and increased knowledge of human markers of depression. Copyright ? 2001 John Wiley & Sons, Ltd.
ER  - 

TY  - JOUR
TI  - Oral Presentations
JO  - Journal of Inherited Metabolic Disease
JA  - J Inherit Metab Dis
VL  - 41
IS  - S1
SN  - 0141-8955
UR  - https://doi.org/10.1007/s10545-018-0233-9
DO  - doi:10.1007/s10545-018-0233-9
SP  - 37
EP  - 219
PY  - 2018
ER  - 

TY  - JOUR
AU  - Daigo, Kenji
AU  - Inforzato, Antonio
AU  - Barajon, Isabella
AU  - Garlanda, Cecilia
AU  - Bottazzi, Barbara
AU  - Meri, Seppo
AU  - Mantovani, Alberto
TI  - Pentraxins in the activation and regulation of innate immunity
JO  - Immunological Reviews
JA  - Immunol Rev
VL  - 274
IS  - 1
SN  - 0105-2896
UR  - https://doi.org/10.1111/imr.12476
DO  - doi:10.1111/imr.12476
SP  - 202
EP  - 217
KW  - cancer-related inflammation
KW  - complement activation
KW  - inflammation
KW  - opsonization
KW  - pentraxins
KW  - PTX3
PY  - 2016
AB  - Summary Humoral fluid phase pattern recognition molecules (PRMs) are a key component of the activation and regulation of innate immunity. Humoral PRMs are diverse. We focused on the long pentraxin PTX3 as a paradigmatic example of fluid phase PRMs. PTX3 acts as a functional ancestor of antibodies and plays a non-redundant role in resistance against selected microbes in mouse and man and in the regulation of inflammation. This molecule interacts with complement components, thus modulating complement activation. In particular, PTX3 regulates complement-driven macrophage-mediated tumor progression, acting as an extrinsic oncosuppressor in preclinical models and selected human tumors. Evidence collected over the years suggests that PTX3 is a biomarker and potential therapeutic agent in humans, and pave the way to translation of this molecule into the clinic.
ER  - 

TY  - JOUR
TI  - Abstracts Programme
JO  - European Journal of Heart Failure
JA  - Eur J Heart Fail
VL  - 21
IS  - S1
SN  - 1388-9842
UR  - https://doi.org/10.1002/ejhf.1488
DO  - doi:10.1002/ejhf.1488
SP  - 5
EP  - 592
PY  - 2019
ER  - 

TY  - JOUR
TI  - Posters A51
JO  - Clinical and Experimental Pharmacology and Physiology
VL  - 31
IS  - s1
SN  - 0305-1870
UR  - https://doi.org/10.1111/j.1440-1681.2004.cep_4027.pdf.x
DO  - doi:10.1111/j.1440-1681.2004.cep_4027.pdf.x
SP  - A51
EP  - A202
PY  - 2004
ER  - 

TY  - JOUR
TI  - Abstracts 416–623
JO  - Hepatology
JA  - Hepatology
VL  - 50
IS  - S4
SN  - 0270-9139
UR  - https://doi.org/10.1002/hep.23302
DO  - doi:10.1002/hep.23302
SP  - 502A
EP  - 599A
PY  - 2009
ER  - 

TY  - JOUR
TI  - Posters
JO  - Mycoses
JA  - Mycoses
VL  - 56
IS  - s2
SN  - 0933-7407
UR  - https://doi.org/10.1111/myc.12110
DO  - doi:10.1111/myc.12110
SP  - 14
EP  - 28
PY  - 2013
ER  - 

TY  - JOUR
TI  - Abstracts of the IPITA-IXA-CTS 2015 Joint Congress November 15–19, 2015, Melbourne, Australia
JO  - Xenotransplantation
JA  - Xenotransplantation
VL  - 22
IS  - S1
SN  - 0908-665X
UR  - https://doi.org/10.1111/xen.12207
DO  - doi:10.1111/xen.12207
SP  - S185
EP  - S201
PY  - 2015
ER  - 

TY  - JOUR
TI  - 2017 ACVIM Forum Research Abstract Program
JO  - Journal of Veterinary Internal Medicine
JA  - J Vet Intern Med
VL  - 31
IS  - 4
SN  - 0891-6640
UR  - https://doi.org/10.1111/jvim.14778
DO  - doi:10.1111/jvim.14778
SP  - 1225
EP  - 1361
PY  - 2017
ER  - 

TY  - JOUR
TI  - Poster Session
JO  - Nephrology
JA  - Nephrology
VL  - 19
IS  - S2
SN  - 1320-5358
UR  - https://doi.org/10.1111/nep.12237
DO  - doi:10.1111/nep.12237
SP  - 77
EP  - 202
PY  - 2014
ER  - 

TY  - JOUR
TI  - Program: Seventeenth annual meeting of The American Society for Bone and Mineral Research
JO  - Journal of Bone and Mineral Research
JA  - J Bone Miner Res
VL  - 10
IS  - S1
SN  - 0884-0431
UR  - https://doi.org/10.1002/jbmr.5650101302
DO  - doi:10.1002/jbmr.5650101302
SP  - S1
EP  - S514
PY  - 1995
ER  - 

C7  - pp. 3441-3551
TI  - Index
SN  - 9781405169110
UR  - https://doi.org/10.1002/9781444303254.index
DO  - doi:10.1002/9781444303254.index
SP  - 3441-3551
PY  - 1995
ER  - 

TY  - JOUR
TI  - Scientific Abstracts
JO  - Pediatric Transplantation
VL  - 13
IS  - s1
SN  - 9781405169110
UR  - https://doi.org/10.1111/j.1399-3046.2009.01146.x
DO  - doi:10.1111/j.1399-3046.2009.01146.x
SP  - 46
EP  - 156
PY  - 2009
ER  - 

TY  - JOUR
TI  - Nautilus and Triton, 17:00-19:00
JO  - International Journal of Developmental Neuroscience
JA  - International Journal of Developmental Neuroscience
VL  - 26
IS  - 8
SN  - 9781405169110
UR  - https://doi.org/10.1016/j.ijdevneu.2008.09.050
DO  - doi:10.1016/j.ijdevneu.2008.09.050
SP  - 841
EP  - 866
PY  - 2008
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Nephrology
VL  - 8
IS  - s1
SN  - 9781405169110
UR  - https://doi.org/10.1046/j.1440-1797.8.s1.3.x
DO  - doi:10.1046/j.1440-1797.8.s1.3.x
SP  - A1
EP  - A53
PY  - 2003
ER  - 

TY  - JOUR
TI  - Published Only
JO  - Journal of Gastroenterology and Hepatology
VL  - 19
IS  - s5
SN  - 9781405169110
UR  - https://doi.org/10.1111/j.1440-1746.2004.03622.x
DO  - doi:10.1111/j.1440-1746.2004.03622.x
SP  - A501
EP  - A667
PY  - 2004
ER  - 

TY  - JOUR
TI  - Posters
JO  - Journal of Peptide Science
JA  - J. Pept. Sci.
VL  - 18
IS  - S1
SN  - 9781405169110
UR  - https://doi.org/10.1002/psc.2449
DO  - doi:10.1002/psc.2449
SP  - S58
EP  - S200
PY  - 2012
AB  - No abstract is available for this article.
ER  - 

TY  - JOUR
TI  - 14th ISN MEETING, MONTPELLJER, FRANCE
JO  - Journal of Neurochemistry
VL  - 61
IS  - s1
SN  - 9781405169110
UR  - https://doi.org/10.1111/j.1471-4159.1993.tb13441.x
DO  - doi:10.1111/j.1471-4159.1993.tb13441.x
SP  - 1
EP  - 285
PY  - 1993
ER  - 

TY  - JOUR
TI  - Abstracts for the Annual Scientific Meeting of the Thoracic Society of Australia & New Zealand ‘Maintaining Lung Health from Cradle to Grave’ 7–12 April 2000, Melbourne, Australia
JO  - Respirology
VL  - 5
IS  - S1
SN  - 9781405169110
UR  - https://doi.org/10.1111/resp.2000.5.s1.a1
DO  - doi:10.1111/resp.2000.5.s1.a1
SP  - A1
EP  - A73
PY  - 2000
ER  - 
